Investor Relations
Corporate Profile
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
- Change
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Apr 26
2024
2024
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Learn More >
Apr 09
2024
2024
Allogene Therapeutics Announces Q2 Investor Conference Participation
Learn More >
Mar 14
2024
2024
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Learn More >
Mar 12
2024
2024
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Learn More >
Mar 05
2024
2024
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Learn More >
Feb 28
2024
2024
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
Learn More >
Feb 16
2024
2024
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
Learn More >
Jan 16
2024
2024
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Learn More >
Jan 04
2024
2024
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Learn More >
Jan 04
2024
2024
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Learn More >